Skip to main content
. 2018 Feb 2;33(1):485–495. doi: 10.1080/14756366.2018.1428572

Figure 1.

Figure 1.

Clinically used sulphonamides/sulphamates with CA inhibitory action (A–S) and SLC-0111 (T) in phase II clinical trials as an antitumour/antimetastatic agent18,19.